Managing RSV Risk for Pregnant Patients & Infants

Physician Fact Sheet (PDF download)  

Two Options for RSV Protection in Infants:

There are two safe and effective immunizations to prevent RSV-associated lower respiratory tract infections (LRTIs) in infants¹ - RSVpreF (Abrysvo) & Nirsevimab (Beyfortus).  Most infants will only need to be protected by one of these vaccines.

RSVpreF (Abrysvo) vaccine is approved for maternal adult use during pregnancy to protect infants through 6 months from RSV-associated LRTI. A single dose of the vaccine should be administered from 32 through 36 weeks of gestation.

OR

Nirsevimab (Beyfortus) RSV monoclonal antibody is an approved vaccine for infants.⁴ Infants younger than 8 months born during or entering their first RSV season are recommended to get only a single dose (i.e., one shot) if⁵:

• The patient who was pregnant did not receive RSV vaccination during pregnancy.
• The patient who was pregnant has an unknown RSV vaccination status.
• The infant was born within 14 days of maternal RSV vaccination.

Some infants 8-19 months who have an increased risk for severe RSV disease and are entering their second RSV season are also recommended to get a dose of nirsevimab.

Fact Sheet References